PhaseBio Announces Acceptance of Late-Breaking Clinical Trial Submission of PB2452 Phase 1 Clinical Trial Results for Present...
March 04 2019 - 8:00AM
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel therapies for orphan diseases, today
announced that results from the Phase 1 clinical trial of PB2452, a
novel reversal agent for the antiplatelet drug ticagrelor, have
been selected for oral presentation during a featured clinical
research session at the American College of Cardiology’s 68th
Annual Scientific Session (ACC.19), being held March 16-18, 2019,
at the Ernest N. Morial Convention Center in New Orleans.
Presentation details are as follows:
Title: First Randomized Human Experience with a
Ticagrelor Reversal AgentSession: Late-Breaking
Clinical Trials, Featured Clinical Research II:
InterventionalSession Number: 408Date /
Time: Sunday, March 17, 2-2:10 p.m.
CDTLocation: Ernest N. Morial Convention Center,
Room 206Presenter: Deepak L. Bhatt, M.D., M.P.H.;
Brigham and Women’s Hospital and Harvard Medical School
Additional information on the scientific session
can be found on the ACC website:
https://accscientificsession.acc.org/.
About PB2452
PB2452 is a novel recombinant human monoclonal
antibody antigen-binding fragment, or Fab fragment, designed to
reverse the antiplatelet activity of ticagrelor in major bleeding
and urgent surgery situations. In clinical and preclinical studies,
PB2452 achieved immediate and sustained reversal of ticagrelor’s
antiplatelet activity, thereby providing a potential life-saving
therapeutic benefit by increasing the safety of ticagrelor, which
like all other antiplatelet drugs, has an increased risk of
bleeding. There are currently no approved reversal agents for
ticagrelor or any other antiplatelet drugs.
About PhaseBio
PhaseBio Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company focused on the development
and commercialization of novel therapies to treat orphan diseases,
with an initial focus on cardiopulmonary disorders. The company’s
lead development candidate is PB2452, a novel reversal agent for
the antiplatelet therapy ticagrelor. PhaseBio is also leveraging
its proprietary elastin-like polypeptide (“ELP”) technology
platform to develop therapies with the potential for less-frequent
dosing and improved pharmacokinetics. PhaseBio’s second product
candidate PB1046, which is based on ELP, is a once-weekly
vasoactive intestinal peptide receptor agonist for the treatment of
pulmonary arterial hypertension.
PhaseBio is located in Malvern, PA and San
Diego, CA. For more information, please
visit www.phasebio.com.
Investor Contact:John SharpPhaseBio
Pharmaceuticals, Inc. Chief Financial Officer(610)
981-6506john.sharp@phasebio.com
Media Contact:Sarah Hall6 Degrees(215)
313-5638shall@6degreespr.com
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Jun 2024 to Jul 2024
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Jul 2023 to Jul 2024